Changes in Musculoskeletal System and Metabolism in Osteoporotic Rats Treated With Urocortin

Area of Science:

• Endocrinology
• Gerontology
• Muscle Physiology

Background:

• Postmenopausal osteoporosis and frailty syndrome contribute to bone and muscle loss in aging populations.
• Simultaneous treatment for both conditions is crucial to prevent falls and injuries.
• Urocortin (UCN) shows potential for improving osteoporotic bone, but its muscle effects are unknown.

Purpose of the Study:

• To investigate the in vivo effects of UCN on skeletal muscle structure in osteopenic rats.
• To evaluate UCN's impact on muscle fiber size and capillary density.
• To assess UCN's effects on bone properties and serum parameters.

Main Methods:

• Ovariectomized (OVX) and sham-operated (SHAM) Sprague-Dawley rats were used.
• OVX rats received UCN (low/high dose) or estradiol (positive control) for 35 days.
• Muscle (gastrocnemius, longissimus, soleus) and tibia analyses included fiber typing, biomechanics, and micro-CT.

Main Results:

• UCN positively influenced the fiber diameter of the M. soleus muscle.
• No significant changes were observed in the biomechanical or structural parameters of bone in UCN-treated rats.
• Elevated serum cholesterol, glucose, and triglyceride levels were noted in the high-dose UCN group.

Conclusions:

• Urocortin demonstrates potential for therapeutic applications in estrogen deficiency, particularly for muscle health.
• Further research is needed to address the observed increases in serum lipids associated with UCN treatment.
• UCN's lack of effect on bone tissue in this model requires additional study.